HRP20180443T1 - Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe - Google Patents
Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe Download PDFInfo
- Publication number
- HRP20180443T1 HRP20180443T1 HRP20180443TT HRP20180443T HRP20180443T1 HR P20180443 T1 HRP20180443 T1 HR P20180443T1 HR P20180443T T HRP20180443T T HR P20180443TT HR P20180443 T HRP20180443 T HR P20180443T HR P20180443 T1 HRP20180443 T1 HR P20180443T1
- Authority
- HR
- Croatia
- Prior art keywords
- nanoparticle
- protein
- complex
- gpcr
- nanoparticle according
- Prior art date
Links
- 102000007474 Multiprotein Complexes Human genes 0.000 title 1
- 108010085220 Multiprotein Complexes Proteins 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 claims 23
- 108091006027 G proteins Proteins 0.000 claims 11
- 102000030782 GTP binding Human genes 0.000 claims 11
- 108091000058 GTP-Binding Proteins 0.000 claims 11
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- -1 GDP or GTP Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 claims 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4722—G-proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (20)
1. Nanočestica (VHH), naznačena time, da sadržava aminokiselinsku sekvencu koja se sastoji od 4 okvirna područja (FR1 do FR4) i 3 komplementarna područja za određivanje (CDR1 do CDR3) prema sljedećoj formuli (1):
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1),
pri čemu navedena nanočestica ima aminokiselinsku sekvencu SEQ ID NO: 1 ili aminokiselinsku sekvencu koja ima najmanje 80% identičnu aminokiselinu s aminokiselinskom sekvencom SEQ ID NO: 1, pri čemu je navedena nanočestica usmjerena protiv i / ili specifično se veže na kompleks koji sadržava GPCR i G protein, i pri čemu se navedena nanočestica specifično veže na G protein, a ne na GPCR u kompleksu.
2. Nanočestica u skladu s patentnim zahtjevom 1, naznačena time, da ima veći afinitet vezanja prema kompleksu u usporedbi s vezanjem na heterotrimerni G protein.
3. Nanočestica u skladu s patentnim zahtjevom 1, naznačena time, da kompleks nadalje sadržava ligand receptora.
4. Nanočestica u skladu s patentnim zahtjevom 3, naznačena time, da je navedeni ligand receptor agonist.
5. Nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time,
da je G protein prisutan u obliku bez nukleotida.
6. Nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da specifično veže konformacijski epitop na sučelju između alfa i beta podjedinice spomenutog G proteina.
7. Nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time, da
a) sprječava ili inhibira disocijaciju kompleksa u prisutnosti nukleotida, ili
b) sprječava ili inhibira vezanje nukleotida na G protein, ili
c) može premjestiti nukleotide iz G proteina.
8. Nanočestica u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačena time, da su spomenuti nukleotidi gvaninski nukleotidi, kao stoje GDP ili GTP, ili njihovi analozi, kao što je GTPγS.
9. Nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time, da je GPCR u aktivnoj konformaciji.
10. Nanočestica u skladu s bilo kojim od patentnih zahtjeva od 1 do 9, naznačena time, da je G protein odabran iz skupine koju čine Gs, Gi, Go, Gt, Ggust, Gz, Golf, Gq, G12, G13.
11. Nanočestica u skladu s bilo kojim od patentnih zahtjeva od 1 do 10, naznačena time, da se navedena nanočestica sastoji od polipeptida.
12. Kompleks, naznačen time, da sadržava nanočesticu u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
13. Sekvenca nukleinske kiseline, naznačena time, da kodira aminokiselinsku sekvencu nanočestice u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
14. Rekombinantni vektor, naznačen time, da sadržava sekvencu nukleinske kiseline u skladu s patentnim zahtjevom 13.
15. Stanica, naznačena time, da sadržava vektor u skladu s patentnim zahtjevom 14 ili sekvencu nukleinske kiseline u skladu s patentnim zahtjevom 13.
16. Upotreba nanočestice u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačena time, da stabilizira in vitro kompleks koji sadržava GPCR i G protein i po izboru ligand receptora u aktivnoj konformaciji.
17. Upotreba nanočestice u skladu s patentnim zahtjevom 16, naznačena time, da
se time sprječava disocijacija kompleksa u prisutnosti nukleotida, naročito gvaninskih nukleotida ili njihovih analoga, kao što je GTPγS.
18. Upotreba nanočestica kako je definirano u bilo kojem od patentnih zahtjeva 1 do 11, naznačena time, da se time kristalizira i / ili otapa strukturu kompleksa koji sadržava GPCR i G protein i opcijski ligand receptora.
19. Upotreba nanočestica kako je definirano u bilo kojem od patentnih zahtjeva 1 do 11 ili stanice kako je definirano u patentnom zahtjevu 15, ili membranskog pripravka stanice kako je definirano u patentnom zahtjevu 15, naznačena time, da joj je svrha izlučivanje spojeva koji moduliraju signalnu aktivnost GPCR-a.
20. Postupak in vitro hvatanja i / ili pročišćavanja kompleksa koji sadržava GPCR i G protein, naznačen time, da postupak sadržava korake:
a. priprema nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 11,
b. omogućavanje vezanja nanočestice na kompleks koji sadržava GPCR i G protein i opcionalno receptor ligand i
c. izborno, izoliranje kompleksa dobivenog u koraku b).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161571159P | 2011-06-21 | 2011-06-21 | |
| EP11181357 | 2011-09-15 | ||
| EP12730478.0A EP2723764B1 (en) | 2011-06-21 | 2012-06-21 | Binding domains directed against gpcr: g protein complexes and uses derived thereof |
| PCT/EP2012/062036 WO2012175643A2 (en) | 2011-06-21 | 2012-06-21 | Binding domains directed against gpcr:g protein complexes and uses derived thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180443T1 true HRP20180443T1 (hr) | 2018-04-20 |
Family
ID=47423019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180443TT HRP20180443T1 (hr) | 2011-06-21 | 2018-03-15 | Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9695227B2 (hr) |
| EP (3) | EP2723764B1 (hr) |
| JP (2) | JP6164535B2 (hr) |
| CN (2) | CN104053667B (hr) |
| AU (1) | AU2012273987B2 (hr) |
| CA (1) | CA2839834A1 (hr) |
| DK (1) | DK2723764T3 (hr) |
| ES (1) | ES2662372T3 (hr) |
| HR (1) | HRP20180443T1 (hr) |
| HU (1) | HUE036982T2 (hr) |
| NO (1) | NO2723764T3 (hr) |
| PL (1) | PL2723764T3 (hr) |
| PT (1) | PT2723764T (hr) |
| WO (1) | WO2012175643A2 (hr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| DK2723764T3 (en) | 2011-06-21 | 2018-03-12 | Vib Vzw | Binding domains targeting GPCR: G protein complexes and uses derived therefrom |
| EP2867674B1 (en) | 2012-06-28 | 2018-10-10 | UCB Biopharma SPRL | A method for identifying compounds of therapeutic interest |
| TWI646230B (zh) | 2013-08-05 | 2019-01-01 | 扭轉生物科技有限公司 | 重新合成之基因庫 |
| US10174115B2 (en) | 2014-07-04 | 2019-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale | Anti-mGluR2 conformational single domain antibodies and uses thereof |
| US20170316147A1 (en) | 2014-10-27 | 2017-11-02 | King Abdullah University Of Science And Technology | Methods and systems for identifying ligand-protein binding sites |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| JP6982362B2 (ja) | 2015-09-18 | 2021-12-17 | ツイスト バイオサイエンス コーポレーション | オリゴ核酸変異体ライブラリーとその合成 |
| CN113604546A (zh) | 2015-09-22 | 2021-11-05 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| CN108603307A (zh) | 2015-12-01 | 2018-09-28 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| CN105802970A (zh) * | 2016-05-30 | 2016-07-27 | 东北师范大学 | 靶向沉默Gβ1的shRNA |
| AU2017315294B2 (en) | 2016-08-22 | 2023-12-21 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
| CN110248724B (zh) | 2016-09-21 | 2022-11-18 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| CN107037116B (zh) * | 2016-12-01 | 2019-04-23 | 白波 | 检测gpcr之间相互作用及其交界面的方法 |
| EA201991262A1 (ru) | 2016-12-16 | 2020-04-07 | Твист Байосайенс Корпорейшн | Библиотеки вариантов иммунологического синапса и их синтез |
| CN110892485B (zh) | 2017-02-22 | 2024-03-22 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| US10894959B2 (en) | 2017-03-15 | 2021-01-19 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| US10696965B2 (en) | 2017-06-12 | 2020-06-30 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| KR20200047706A (ko) * | 2017-09-11 | 2020-05-07 | 트위스트 바이오사이언스 코포레이션 | Gpcr 결합 단백질 및 이의 합성 방법 |
| US10894242B2 (en) | 2017-10-20 | 2021-01-19 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| KR20200091400A (ko) | 2017-10-31 | 2020-07-30 | 브이아이비 브이지더블유 | 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도 |
| JP7343488B2 (ja) * | 2017-12-21 | 2023-09-12 | フイルメニツヒ ソシエテ アノニム | 匂い物質受容体のためのポジティブなアロステリックモジュレーターを同定するための方法 |
| EP3735459A4 (en) | 2018-01-04 | 2021-10-06 | Twist Bioscience Corporation | DNA-BASED DIGITAL INFORMATION STORAGE |
| WO2019155041A1 (en) * | 2018-02-12 | 2019-08-15 | Vib Vzw | Gβγ COMPLEX ANTIBODIES AND USES THEREOF |
| CN108586620B (zh) * | 2018-05-10 | 2021-11-23 | 山东大学 | 筛选昆虫性信息素受体的配体的传感器分子以及筛选方法 |
| CN112639130B (zh) | 2018-05-18 | 2024-08-09 | 特韦斯特生物科学公司 | 用于核酸杂交的多核苷酸、试剂和方法 |
| FR3084365B1 (fr) | 2018-07-27 | 2020-10-23 | Cisbio Bioassays | Anticorps a domaine unique qui se lient a la proteine g alpha |
| US20220064245A1 (en) * | 2018-12-21 | 2022-03-03 | Vib Vzw | Fusion proteins comprising a cytokine and scaffold protein |
| FR3092172B1 (fr) * | 2019-01-30 | 2021-02-12 | Cisbio Bioassays | Méthode pour mesurer la modulation de l’activation d’un récepteur couplé à une protéine G avec des analogues du GTP |
| SG11202109322TA (en) | 2019-02-26 | 2021-09-29 | Twist Bioscience Corp | Variant nucleic acid libraries for glp1 receptor |
| CA3131691A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| KR20220012857A (ko) * | 2019-04-29 | 2022-02-04 | 콘포 테라퓨틱스 엔.브이. | 트랜스맴브레인 단백질, 특히 gpcr과 함께 사용하기 위한 스크리닝 방법 및 검정 |
| WO2020257405A1 (en) * | 2019-06-18 | 2020-12-24 | Musc Foundation For Research Development | Compositions and methods targeting the nucleotide free state of ras to block oncogenic signaling and transformation |
| CA3144644A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| KR20220066151A (ko) | 2019-09-23 | 2022-05-23 | 트위스트 바이오사이언스 코포레이션 | Crth2에 대한 변이체 핵산 라이브러리 |
| FR3106830B1 (fr) | 2020-01-30 | 2022-02-11 | Cisbio Bioassays | Anticorps anti-protéine G alpha |
| WO2023154533A2 (en) * | 2022-02-14 | 2023-08-17 | Twist Bioscience Corporation | Combinatorial dna assembly for multispecific antibodies |
| WO2023159144A2 (en) * | 2022-02-17 | 2023-08-24 | The Regents Of The University Of Michigan | G-protein coupled receptor assay |
| CN114702570B (zh) * | 2022-03-23 | 2022-12-06 | 山东大学 | aGPCR拮抗剂 |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| US11862295B1 (en) | 2022-11-08 | 2024-01-02 | United Arab Emirates University | Method of classifying conformers |
| CN116425888A (zh) * | 2023-04-24 | 2023-07-14 | 徐州医科大学 | 一种多肽tat-v2r1c及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| EP1051493A2 (en) | 1998-01-26 | 2000-11-15 | Unilever Plc | Method for producing antibody fragments |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| AU2001268855A1 (en) | 2000-05-26 | 2001-12-03 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| US7208279B2 (en) | 2001-03-14 | 2007-04-24 | Caden Biosciences, Inc. | Method for identifying inhibitors of G protein coupled receptor signaling |
| US7294472B2 (en) * | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| WO2004035614A1 (en) * | 2001-07-11 | 2004-04-29 | Karo Bio Ab | Synthetic or partially purified peptides which can bind to specific subunits of g proteins and uses thereof |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| EP1578842B1 (en) | 2002-12-31 | 2009-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| US9029097B2 (en) * | 2005-02-16 | 2015-05-12 | Universite De Montreal | Biosensors for monitoring receptor-mediated G-protein activation |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US7947807B2 (en) * | 2007-10-15 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3) |
| MX2010012518A (es) * | 2008-05-16 | 2010-12-06 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos. |
| WO2009147196A1 (en) | 2008-06-04 | 2009-12-10 | Vib Vzw | Hiv-rev-multimerization inhibiting nanobodies |
| EP2352764B1 (en) * | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| US20110294983A1 (en) | 2008-12-08 | 2011-12-01 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| DK2723764T3 (en) | 2011-06-21 | 2018-03-12 | Vib Vzw | Binding domains targeting GPCR: G protein complexes and uses derived therefrom |
-
2012
- 2012-06-21 DK DK12730478.0T patent/DK2723764T3/en active
- 2012-06-21 ES ES12730478.0T patent/ES2662372T3/es active Active
- 2012-06-21 PL PL12730478T patent/PL2723764T3/pl unknown
- 2012-06-21 WO PCT/EP2012/062036 patent/WO2012175643A2/en active Application Filing
- 2012-06-21 PT PT127304780T patent/PT2723764T/pt unknown
- 2012-06-21 JP JP2014516358A patent/JP6164535B2/ja active Active
- 2012-06-21 CN CN201280040585.9A patent/CN104053667B/zh active Active
- 2012-06-21 HU HUE12730478A patent/HUE036982T2/hu unknown
- 2012-06-21 EP EP12730478.0A patent/EP2723764B1/en active Active
- 2012-06-21 EP EP23193788.9A patent/EP4282882A3/en active Pending
- 2012-06-21 CA CA2839834A patent/CA2839834A1/en active Pending
- 2012-06-21 NO NO12730478A patent/NO2723764T3/no unknown
- 2012-06-21 AU AU2012273987A patent/AU2012273987B2/en active Active
- 2012-06-21 US US14/129,100 patent/US9695227B2/en active Active
- 2012-06-21 CN CN201710728087.8A patent/CN107857810A/zh active Pending
- 2012-06-21 EP EP17209368.4A patent/EP3345919A1/en active Pending
-
2017
- 2017-02-16 JP JP2017026632A patent/JP2017127306A/ja active Pending
- 2017-05-01 US US15/583,540 patent/US10626154B2/en active Active
-
2018
- 2018-03-15 HR HRP20180443TT patent/HRP20180443T1/hr unknown
-
2020
- 2020-04-17 US US16/852,235 patent/US20200239534A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013032451A2 (pt) | 2016-11-22 |
| US20200239534A1 (en) | 2020-07-30 |
| JP6164535B2 (ja) | 2017-07-19 |
| AU2012273987B2 (en) | 2017-01-05 |
| CN107857810A (zh) | 2018-03-30 |
| US9695227B2 (en) | 2017-07-04 |
| CA2839834A1 (en) | 2012-12-27 |
| EP4282882A3 (en) | 2024-03-06 |
| HUE036982T2 (hu) | 2018-08-28 |
| PT2723764T (pt) | 2018-03-09 |
| US20140275487A1 (en) | 2014-09-18 |
| CN104053667B (zh) | 2017-09-15 |
| JP2014525735A (ja) | 2014-10-02 |
| WO2012175643A2 (en) | 2012-12-27 |
| US20170253644A1 (en) | 2017-09-07 |
| AU2012273987A1 (en) | 2014-01-30 |
| NO2723764T3 (hr) | 2018-05-26 |
| EP2723764B1 (en) | 2017-12-27 |
| EP2723764A2 (en) | 2014-04-30 |
| PL2723764T3 (pl) | 2018-05-30 |
| ES2662372T3 (es) | 2018-04-06 |
| JP2017127306A (ja) | 2017-07-27 |
| DK2723764T3 (en) | 2018-03-12 |
| EP4282882A2 (en) | 2023-11-29 |
| CN104053667A (zh) | 2014-09-17 |
| WO2012175643A3 (en) | 2013-06-13 |
| EP3345919A1 (en) | 2018-07-11 |
| US10626154B2 (en) | 2020-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180443T1 (hr) | Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe | |
| JP2014525735A5 (hr) | ||
| HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela | |
| HRP20171777T1 (hr) | Novi himerni polipeptidi za potrebe probira i otkrivanja lijekova | |
| HRP20200464T1 (hr) | Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera | |
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| HRP20191775T1 (hr) | Multispecifične konstrukcije antitijela | |
| HRP20230623T1 (hr) | Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom | |
| EA201370076A1 (ru) | Иммуноглобулины-переносчики и их применение | |
| HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
| NZ607969A (en) | Cd33 binding agents | |
| RU2018132044A (ru) | Антитела против тау | |
| FI3835310T3 (fi) | Fibronektiinipohjaisia telinedomeeniproteiineja, jotka sitoutuvat myostatiiniin | |
| JP2014518898A5 (hr) | ||
| EA201791134A1 (ru) | Полипептиды химерного фактора viii и их применение | |
| FI3378535T3 (fi) | Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita | |
| NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| TR201909663T4 (tr) | Formil peptit reseptör benzeri-1 (fprl-1) reseptör modülatörleri olarak 2,5-dioksoimidazolidin-1-il-3-fenilüre türevleri. | |
| UA115781C2 (uk) | Cx3cr1-зв'язуючий поліпептид | |
| UA120047C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
| WO2015066379A3 (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide | |
| SI2831105T1 (en) | FUZIJA TGF TIPA II AND III RECEPTORS | |
| WO2012091564A3 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis | |
| EA033437B1 (ru) | Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний | |
| CA2863661C (en) | Diagnostic peptides for lyme disease |